Chong Kun Dang said it would exclusively market Baxter Korea’s Caelyx, a recurrent ovarian cancer treatment, in Korea. Under the contract, Chong Kun Dang will distribute, sell, and market Caelyx to Korean hospitals and clinics from July.

Chong Kun Dang will exclusively market Baxter’s ovarian cancer treatment Caelyx in Korea.
Chong Kun Dang will exclusively market Baxter’s ovarian cancer treatment Caelyx in Korea.

“We will strategically conduct distribution, sales, and marketing of Caelyx using sales power and know-how accumulated through Camtobel, an ovarian cancer treatment developed by Chong Kun Dang,” a company official said. “Through continuous cooperation with Baxter Korea, we plan to strengthen our recurrent ovarian cancer treatment market position.”

Caelyx features a mechanism in which doxorubicin, the main component of the drug, is encapsulated in a liposome applied with pegylation platform technology to deliver the drug only to cancer cells.

Compared to the existing doxorubicin drug, it has fewer side effects, including cardiac toxicity and hair loss with long-lasting efficacy.

The product received approval from the U.S. Food and Drug Administration in 1995 and has treated ovarian cancer patients in global markets, including the U.S. and Europe. In 2021, the National Comprehensive Cancer Network (NCCN) guidelines recommended the drug as the preferred treatment for platinum-sensitive and resistant recurrent ovarian cancer patients.

Copyright © KBR Unauthorized reproduction, redistribution prohibited